A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM.
Phase of Trial: Phase I/II
Latest Information Update: 27 Jun 2014
At a glance
- Drugs LIK 066 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 11 Jan 2013 Actual initiation date changed from Jul 2011 to Jun 2011 as reported by ClinicalTrials.gov.
- 11 Jan 2013 Planned End Date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 11 Jan 2013 Planned number of patients changed from 136 to 168 as reported by ClinicalTrials.gov.